13th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220096424 | TREATMENT OF CARDIAC DYSFUNCTION - A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof. | 2022-03-31 |
20220096425 | ANTIVIRAL COMPOSITION FOR SARS-COV-2 CONTAINING CANNABINOIDS AS ACTIVE INGREDIENT - The present invention relates to an antiviral composition and a screening method thereof for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that occurred in Wuhan, China in 2019. An extract from leaves or unfertilized female flowers of | 2022-03-31 |
20220096426 | Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis - The present invention relates to a compound of the following general formula (I): | 2022-03-31 |
20220096427 | APPARATUSES, METHODS, AND SYSTEMS FOR EXTRACTION, ISOLATION AND CONVERSION OF VARIOUS CANNABINOIDS, AND MODIFICATIONS OF WHOLE-PLANT HEMP EXTRACTS THEREWITH - Apparatuses, methods, and systems for extraction, isolation, purification, and conversion of various cannabinoids, and modifications of whole-plant hemp extracts therewith are presented. A method for preparing a whole-plant hemp extract based product includes extracting cannabinoids from plant materials, such as one or more hemp varieties of | 2022-03-31 |
20220096428 | Method for Treating Osteoarthritis Pain by Administering Resiniferatoxin - Disclosed herein are methods of administering resiniferatoxin (RTX) for treatment of osteoarthritis (OA) pain, and compositions for use in such methods. | 2022-03-31 |
20220096429 | MDMA TREATMENT TO ENHANCE ACUTE EMOTIONAL EFFECTS PROFILE OF LSD, PSILOCYBIN OR OTHER PSYCHEDELICS - A method of enhancing positive therapeutic effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen of MDMA administered in a dose of 20-200 mg, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a psychedelic in the same dosage form. | 2022-03-31 |
20220096430 | DEVICES AND METHODS FOR FACILITATING AND CONTROLLING USE OF A MEDICATION - A device includes a reservoir configured to store a drug formulation including at least one abuse-preventing additive. The device further includes means configured to remove the at least one abuse-preventing additive. The device further includes means configured to prevent access to the drug formulation. | 2022-03-31 |
20220096431 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING, TREATING AND DIAGNOSING A NEURODEGENERATIVE DISEASE - Provided is a pharmaceutical composition and method for preventing, treating and diagnosing a neurodegenerative disease in a subject in need thereof. The method includes obtaining a biological sample from the subject and determining an expression level of a miRNA, and stimulating expression of the miRNA. Also provided is a kit for diagnosing a neurodegenerative disease in a subject in need thereof. | 2022-03-31 |
20220096432 | METHOD FOR TREATING ZIKA VIRUS INFECTION WITH QUERCETIN-CONTAINING COMPOSITIONS - A method for treating Zika virus infection with a composition containing quercetin or isoquercetin, together with one or more of vitamin B3, vitamin C, and a folate compound is described. Methods of preventing microcephaly and treating and preventing infections of other Flavivridae viruses are also described. | 2022-03-31 |
20220096433 | COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION - The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes. | 2022-03-31 |
20220096434 | LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS TO GENERATE BIOCOMPATIBLE OPHTHALMIC FORMULATIONS - The present invention describes ophthalmic lipoic acid choline ester compositions and specific processes to produce biocompatible formulations of said compositions suitable for the eye. | 2022-03-31 |
20220096435 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES - Provided are methods of regulating proliferation and/or differentiation of keratinocytes and immune cells, more specifically to methods of treating pathologies characterized by hyperproliferative keratinocytes or inflammatory skin diseases by administration of FABP4-inhibitor. | 2022-03-31 |
20220096436 | COMBINATION PRODUCT FOR THE TREATMENT OF CANCER - Methods of administering a therapeutically effective amount of Debio 1143, or another IAP antagonist, and a therapeutically effective amount of nivolumab, for the treatment of cancer, are provided. | 2022-03-31 |
20220096437 | ANTIBACTERIAL COMPOUNDS - Described are 1, 2, 4-substituted azetidine compounds of formula I, as well as pharmaceutical compositions and dosage forms comprising the compounds, and their use as a medicament. The compounds may find use as antibacterial agents, in particular against M. tuberculosis. | 2022-03-31 |
20220096438 | METHODS OF TREATING MIGRAINE - The present application relates to a method of reducing a need of rescue medication and/or a need of more than one dose of migraine medication in a patient suffering from cephalic pain, including migraine, cluster headache, episodic migraine, or rapid escalating migraine. In some embodiments, the method includes administering intranasally a composition comprising sumatriptan, or a physiologically-acceptable salt or a solvate thereof, and an alkyl glycoside or a saccharide alkyl ester. | 2022-03-31 |
20220096439 | Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases - A method of maintaining and/or improving barrier function of the skin of a human subject is disclosed herein. An embodiment of the instant method includes orally administering to a subject in need of maintenance and/or improvement of skin barrier function an effective amount of histidine and/or a derivative thereof. In some embodiments, the method may be used on a subject requiring the treatment and/or prevention of a skin disorder or condition. The barrier skin function may be assessed by measuring transepidermal water loss and administering the histidine and/or the derivative thereof in a composition comprising from about 0.5 g to about 7 g total amount of the histidine and/or derivative thereof per single dose. | 2022-03-31 |
20220096441 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS - Compounds, compositions, and methods for the treatment of infections caused by | 2022-03-31 |
20220096442 | METHODS FOR TREATING VIRUS INFECTION OR PROLIFERATION - A method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site-utilizing virus (IRES-utilizing virus) involves administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: | 2022-03-31 |
20220096443 | PHARMACEUTICAL COMPOSITION - Provided is a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and having excellent homogeneity. The pharmaceutical composition is provided to contain the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) and (B-7): (B-1) an alkylcellulose and a salt thereof; and a (meth)acrylic acid-based polymer. | 2022-03-31 |
20220096444 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM - The present invention provides a prophylactic or therapeutic agent for delirium containing compound (I) having melatonin receptor affinity. A compound represented by the formula: | 2022-03-31 |
20220096445 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane, antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2022-03-31 |
20220096446 | USE OF MTOR INHIBITORS FOR PREVENTION OF INTESTINAL POLYP GROWTH AND CANCER - Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR). | 2022-03-31 |
20220096447 | TREATMENT OF RESTENOSIS USING TEMSIROLIMUS - Described herein are methods for distributing temsirolimus to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of temsirolimus for delivery into the tissue surrounding a blood vessel for treating vascular diseases. | 2022-03-31 |
20220096448 | FIBROSIS DRUG - The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier. | 2022-03-31 |
20220096449 | METHOD OF TREATMENT WITH TRADIPITANT - Disclosed herein is a method of treatment of gastroparesis and symptoms thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant. | 2022-03-31 |
20220096450 | Compounds and Methods for Treating or Preventing Heart Failure - The present invention relates to the discovery of compounds that can be used to treat and/or prevent heart failure in a subject. In certain embodiments, the compounds of the invention are sulfide:quinone oxidoreductase (SQOR) inhibitors. In other embodiments, the compounds of the invention increase physiological levels of H | 2022-03-31 |
20220096451 | POLYVALENT DERIVATIVES OF EMOXYPINE - Use of polyvalent emoxypine derivatives or related compounds in the treatment or prevention of, inter alia, Parkinson's Disease are described. | 2022-03-31 |
20220096452 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS - A local anesthetic chosen from the group of amino amide or amino ester, and a composition or pharmaceutical composition including the local anesthetic. The local anesthetic is for use in the treatment of neurological symptoms resulting from brain dysfunctions such as motor, cognitive, sensory, visual deficits, and/or apathetic, catatonic, vegetative and/or minimally conscious states. | 2022-03-31 |
20220096453 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR - Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 | 2022-03-31 |
20220096454 | CARBOXYLIC ACID DERIVATIVES - Compounds of the formula I | 2022-03-31 |
20220096455 | USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION - The present application relates to the use of roluperidone, i.e., Compound (I): | 2022-03-31 |
20220096456 | LIQUID FORMULATIONS OF INDACATEROL - Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure. | 2022-03-31 |
20220096457 | COMPOSITIONS AND METHODS FOR TREATING HELICOBACTER PYLORI INFECTION - A method for treating and/or preventing VacA+ | 2022-03-31 |
20220096458 | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan - Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin. | 2022-03-31 |
20220096459 | RESIQUIMOD TOPICAL AND INJECTABLE COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN CONDITIONS - Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed. | 2022-03-31 |
20220096461 | LIQUID ORAL DOSAGE FORMULATIONS OF METHYLNALTREXONE - Provided herein are pharmaceutical compositions comprising methylnaltrexone, lauryl sulfate or docusate, and at least one of an oil, a surfactant or a cosolvent, wherein the methylnaltrexone and lauryl sulfate or docusate are present as an ion pair. The pharmaceutical compositions may further comprise a surfactant so as to provide self-emulsifying methylnaltrexone delivery systems. | 2022-03-31 |
20220096462 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-03-31 |
20220096463 | LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM - The presently described technology provides compositions of one or more of oxoacids, amino acids, polyethylene glycols, and/or vitamin compounds chemically conjugated to levorphanol ((−)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions of levorphanol. | 2022-03-31 |
20220096464 | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVE - A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist. | 2022-03-31 |
20220096465 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF TRAUMATIC INJURY - The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2022-03-31 |
20220096466 | TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS - This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease. | 2022-03-31 |
20220096467 | COMBINATION OF SELECTIVE ALPHA-ADRENERGIC RECEPTOR AGONIST OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF - The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders. | 2022-03-31 |
20220096468 | Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell - It is an object of the present invention to provide a therapeutic agent for RNA viral infection, comprising a novel combination of a pyrazine derivative and a specific compound, which exhibits effects against an RNA virus, and also to provide a therapeutic agent for RNA viral infection, comprising a combination of a pyrazine derivative and a specific compound, which is capable of simultaneously reinforcing antiviral activities against a plurality of RNA viruses. According to the present invention, provided is a therapeutic agent for RNA viral infection, which comprises a combination of a pyrazine derivative or a salt thereof and a compound which increases the amount of a pyrazine derivative ribose triphosphate in a cell. | 2022-03-31 |
20220096469 | PHARMACEUTICAL COMPOSITIONS - The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections. | 2022-03-31 |
20220096470 | PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN - A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously. | 2022-03-31 |
20220096471 | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES - Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and/or have relapsed or not responded to a prior chemotherapy. | 2022-03-31 |
20220096472 | PIPERIDINE-SUBSTITUTED MNK INHIBITORS AND METHODS RELATED THERETO - The present invention relates to compounds according to Formula (I): | 2022-03-31 |
20220096473 | METHOD FOR TREATING AN ACUTE MYELOID LEUKEMIA - An aspect described herein includes a method for treating acute myeloid leukemia (AML) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule tubulin polymerization inhibitor compound. More particularly, another aspect described herein includes a method for treating acute myeloid leukemia in a subject in need thereof comprising, administering to the subject an effective amount of the small molecule tubulin polymerization inhibitor compound described herein in combination with a chemotherapeutic agent. | 2022-03-31 |
20220096474 | PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION - The present invention relates to high doses of macitentan (INN), i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, the present invention relates to the use of high doses of macitentan or of aprocitentan for the manufacture of a medicament for the treatment and/or prevention of CTEPH, as well as to a method for the treatment and/or prevention of CTEPH comprising administering high doses of macitentan or of aprocitentan to a patient. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of CTEPH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDES) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Moreover, the present invention relates to a pharmaceutical composition for the treatment of CTEPH comprising a high dose of macitentan or of aprocitentan. | 2022-03-31 |
20220096475 | METHOD FOR TREATING SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION - There is a method of treating or preventing sarcoidosis-associated pulmonary hypertension in a patient. The method has the step of administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. | 2022-03-31 |
20220096476 | Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension - The present invention relates to high doses of macitentan, i.e. propylsulfamic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof, or of aprocitentan, for use in the treatment and/or prevention of pulmonary arterial hypertension (PAH). Moreover, the present invention relates to the use of high doses of macitentan, or of aprocitentan, for the manufacture of a medicament for the treatment and/or prevention of PAH, as well as to a method for the treatment and/or prevention of PAH comprising high doses of macitentan or of aprocitentan. Further, the present invention relates to a dosage regimen for the treatment and/or prevention of PAH as well as to a combination of macitentan, or of aprocitentan, with one or more phosphodiesterase type 5 (PDE5) inhibitors, prostacyclin analogues, prostacyclin receptor agonists or soluble guanylate cyclase stimulators. Therein, PAH is preferably mild or moderate PAH. Moreover, the present invention relates to a pharmaceutical composition for the treatment of PAH comprising a high dose of macitentan or of aprocitentan. | 2022-03-31 |
20220096477 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-03-31 |
20220096478 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-03-31 |
20220096479 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-03-31 |
20220096480 | INDOLE MOLECULES AND USE THEREOF IN THE INHIBITION OF DNA POLYMERASES - The present disclosure provides compositions and methods for the inhibition of DNA polymerases. The methods and compositions as described herein are useful in the treatment of cancer. In particular, the present disclosure provides compositions comprising one or more of indole-derived compounds useful in treatment of cancers including those which are resistant to genotoxic therapies. | 2022-03-31 |
20220096481 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS - Provided herein are methods of treating, managing and/or preventing viral infections. A particular method comprises administering to a subject in need thereof an effective amount of an adaptor associated kinase 1 inhibitor of the formula | 2022-03-31 |
20220096482 | COMBINATION THERAPIES - The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a CDK 4/6 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor. | 2022-03-31 |
20220096483 | HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS - Methods of treating a head and neck cancer are disclosed. | 2022-03-31 |
20220096484 | METHODS AND COMPOSITIONS FOR TREATING CANCER BY TARGETING FATP2 AND MYELOID DERIVED SUPPRESSOR CELLS - A method of treating cancer in a subject in need thereof is provided. The method includes administering an agent that inhibits, decreases, deletes or downregulates FATP2. In one embodiment, the method includes administering a checkpoint inhibitor. Also provided are methods of decreasing MDSCs and MDSC immune-suppressive activity in a subject in need thereof. | 2022-03-31 |
20220096485 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE - Functionalized pyrano[2,3-d]pyrimidin-7-one derivatives, methods for making the derivatives, and methods of using the derivatives as protein kinase inhibitors. | 2022-03-31 |
20220096486 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA - The present invention relates to compounds and compositions comprising said compounds, for use in the treatment of ADCY5-related dyskinesia. | 2022-03-31 |
20220096487 | METHODS FOR TREATING HIV WITH DOLUTEGRAVIR AND LAMIVUDINE - Invented are methods for treating HIV in a human in need thereof which comprises the administration of a therapeutically effective amount of a combination of dolutegravir or a pharmaceutically acceptable salt thereof and lamivudine or a pharmaceutically acceptable salt thereof, to such human. | 2022-03-31 |
20220096488 | ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE - Stable oral liquid compositions including chlorpromazine or a pharmaceutically acceptable salt or solvate of chlorpromazine, and methods of administering the compositions, are disclosed. | 2022-03-31 |
20220096489 | ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE - Stable oral liquid compositions including chlorpromazine or a pharmaceutically acceptable salt or solvate of chlorpromazine, and methods of administering the compositions, are disclosed. | 2022-03-31 |
20220096490 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2022-03-31 |
20220096491 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE - Pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt of azelastine, and methylcobalamin are disclosed. Methods of using the pharmaceutical compositions for treating patients with Alzheimer's disease or Parkinson's disease are also disclosed. | 2022-03-31 |
20220096492 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS - The invention provides a complex comprising Zn2+ and a compound of formula (I): or a deuterated analog thereof, or an ion or poly-ion thereof, or a salt thereof that is useful for treating cancer, as well as compositions and kits comprising such complexes. | 2022-03-31 |
20220096493 | PRECIPITATION RESISTANT SMALL MOLECULE DRUG FORMULATIONS - Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation. | 2022-03-31 |
20220096494 | PREVENTION OF PRETERM BIRTH (PTB) BY INHIBITION OF FKBP51 - The disclosure is directed to a method of enhancing progesterone receptor (PR) activity in a mammal, which comprises administering a composition comprising an inhibitor of FK506 binding protein 51 (FKBP51) to a mammal in need thereof, such as a pregnant human female, whereby progesterone receptor activity in the mammal is enhanced as compared to a mammal not administered the composition. The method results in an extension of the gestation period and a decreased likelihood of preterm birth and fetal growth restriction. | 2022-03-31 |
20220096495 | TREATMENT AND PREVENTION OF INTESTINAL INFLAMMATORY DISEASES WITH A BILE ACID DERIVATIVE - The present application relates to methods of treating or preventing an intestinal inflammatory disease or condition (e.g., intestinal ischemia reperfusion injury) in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the application. | 2022-03-31 |
20220096496 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL - Aqueous hydrocortisone sodium phosphate and monothioglycerol formulations are disclosed. | 2022-03-31 |
20220096497 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA - The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof. | 2022-03-31 |
20220096498 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION - Drug-loaded microspheres containing both a steroidal anti-inflammatory drug and a non-steroidal anti-inflammatory drug and injectable formulations containing the microspheres for sustained release of both drugs are disclosed. Methods of making such drug-loaded microspheres, formulations, and use of them for treating pains and inflammations, especially those caused by rheumatoid arthritis or osteoarthritis using such microspheres and formulations are also described. | 2022-03-31 |
20220096499 | DIETARY NUTRIENT COMPOSITIONS - Provided herein are dietary supplement compositions comprising a plurality of beadlets and an oil. Provided herein are also dietary supplement compositions comprising a plurality of mini-tabs and oil. The beadlets or mini-tabs comprise at least one nutrient that is miscible in aqueous solution, and the oil comprises at least one fat-soluble nutrient. The composition may be contained within one or more capsules, and be packaged with a scented insert. | 2022-03-31 |
20220096500 | CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAME - Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided. | 2022-03-31 |
20220096501 | COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAME - The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants. | 2022-03-31 |
20220096502 | TARGETING HYPOXIC CANCER STEM CELLS (CSCS) WITH DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY - The present disclosure relates to inhibitors of mitochondrial function. Methods of treating hypoxic cancer cells using anti-angiogenic agents and mitochondrial biogenesis inhibitors are disclosed. Tetracyclines, such as doxycycline, may serve as milochondrial biogenesis inhibitors. Also described are methods of sensitizing hypoxic cancer cells to one or more chemotherapies by administering a milochondrial biogenesis inhibitor with the chemotherapy. | 2022-03-31 |
20220096503 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND METHODS THEREOF - Described herein are combination pharmaceutical compositions including a combination of hydrophilic and hydrophobic therapeutic agents (i.e., drugs) that are assembled together with excipients under specific conditions, forming a homogeneous pharmaceutical powder with unified repetitive multi-drug motif (MDM) structure. Unlike currently available drug combination powders, which are amorphous, the combination pharmaceutical compositions (e.g., combination therapeutic agent powders) of the present disclosure have long range order, in the form of repetitive multi-drug and unified motifs | 2022-03-31 |
20220096504 | METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERS - Provided herein are methods and compositions for the treatment of psychological, cognitive, behavioral, and/or mood disorders, the composition comprising a 5HT agonist (e.g. psilocybin). In certain embodiments, such compositions are administered in amounts or levels high enough to provide a therapeutic effect, but insufficient to provide an adverse effect. | 2022-03-31 |
20220096505 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions. | 2022-03-31 |
20220096506 | Method for Enhancing Tyrosinase Inhibitory Activity - The disclosure provides a method for enhancing tyrosinase inhibitory activity, and belongs to the technical field of intensive and deep processing of fruits and vegetables. The disclosure improves an inhibitory effect of a tyrosinase inhibitor on tyrosinase in manner of heating treatment; the tyrosinase inhibitor consists of a phenolic acid with a concentration of 0.6-1.8 mg/mL and a saponin with a concentration of 0.5-1.5 mg/mL; and the heating treatment conditions are as follows: the heating temperature is 130-170° C., and the heating time is 30-120 min. The disclosure compounds polyphenols and the saponin into the tyrosinase inhibitor, tyrosinase relative activity after treatment can be as low as 5%, and a three-component polyphenol can produce a synergistic effect; high temperature will make the saponin deglycosylated to produce substances with a powerful tyrosinase inhibitory effect, such as a polyphenol polymer, thus greatly improving the inhibitory effect of the tyrosinase inhibitor on the tyrosinase. | 2022-03-31 |
20220096507 | Parenteral Pharmaceutical Composition Comprising Azacitidine or Decitabine in DMSO - The invention relates to a parenteral pharmaceutical composition comprising azacitidine and dimethyl sulfoxide. | 2022-03-31 |
20220096508 | METHOD OF TREATMENT AND PHARMACEUTICAL DOSAGE FORM - The invention relates to a method of treatment of neoplastic disease in a patient with mutant TP53 with a combination of APR-246 and azacitidine, in which APR-246 is given as a fixed dose. The invention also relates to pharmaceutical dosage forms of APR-246 which employ such fixed dose. | 2022-03-31 |
20220096509 | Reformulating Hospital Gentamicin to reduce the risk of hearing loss while maintaining antimicrobial activity - Reformulations of gentamicin for treatment of infections are provided with the goal to reduce current side effects such as ototoxicity, while maintaining antimicrobial activity. The reformulation is a mixture of three of the C-components of gentamicin: C1a, C2a and C2b, while excluding as much as possible, C1 and C2. Specifically, to the objective of this invention a mixture is formulated having gentamicin C1a ranging from 10-30%, gentamicin C2a ranging from 0-30%, and gentamicin C2b ranging from 40-90%, where the mixture totals a 100% of the gentamicin C-components, defined as C1, C1a, C2, C2a and C2b only. The formulations of this invention increase the probability of a more favorable outcome for the patients exposed to gentamicin, i.e., reduced risk of the side-effect of hearing loss. | 2022-03-31 |
20220096510 | METHOD AND PHARMACOLOGICAL COMPOSITION FOR THE PREVENTION OF RECURRENT INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE | 2022-03-31 |
20220096511 | ANTIFUNGAL AGENTS WITH IMPROVED WATER SOLUBILITY - Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a primary amine to the activated polyene macrolide antifungal; reacting for a time sufficient to convert the carboxylic acid to an amide, and quenching the reaction, thus yielding a polyene macrolide amide or salt thereof. Also provided are water-soluble polyene macrolide derivatives. | 2022-03-31 |
20220096512 | WATER-BASED ANTIFUNGAL COMPOSITIONS - Water-based antifungal composition having improved bioavailability; such formulations include a polyene macrolide antifungal agent, such as nystatin, a surfactant, a buffer, an organic amine base; and water. Also provided are methods for preparing water-based antifungal compositions. | 2022-03-31 |
20220096513 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS - The present invention includes CSNK1A1 inhibitors that are useful in treating or preventing a cancer in a subject. In certain embodiments, the cancer comprises a hematological cancer, such as but not limited to acute myeloid leukemia (AML) and/or MDS (myelodysplastic syndrome, including 5q-MDS). In other embodiments, the cancer comprises colon cancer. | 2022-03-31 |
20220096514 | METHODS OF TREATING THYMIDINE KINASE 2 DEFICIENCY BY ADMINISTERING DEOXYCYTIDINE AND DEOXYTHYMIDINE - Provided is a method of treating thymidine kinase 2 (TK2) deficiency in a subject by administering deoxycytidine (dC) and deoxythymidine (dT). The method can include administering dC and dT to a subject in doses between 200 mg/kg/day and 600 mg/kg/day for each of dC and dT. In some cases, the method includes performing test administrations with lower dosages of dC and dT, administering adjusted doses after administration of the target doses, or a combination thereof. | 2022-03-31 |
20220096515 | Methods and Formulations for Preventing Neurological or Psychiatric Disorders - Methods of treatment and pharmaceutical formulations configured to prevent psychiatric diseases and/or disorders in offspring are provided. The methods and treatments use a regulator of angiogenesis pathways. The regulator can restore GABA secretion and neuronal migration. The regulator may be administered during pregnancy of an individual, thus allowing proper development of a fetal brain. | 2022-03-31 |
20220096516 | OLIGONUCLEOTIDE MOLECULE AND APPLICATION THEREOF IN TUMOR THERAPY - The present invention relates to oligomeric nucleic acids and uses thereof for the treatment of tumors. The oligomeric nucleic acid for tumor treatment provided by the present application can be small activating nucleic acid molecules. A small activating nucleic acid molecule of the present invention can be a double-stranded or single-stranded RNA molecule targeting the promoter region of an LHPP gene comprising a first nucleic acid strand and a second nucleic acid strand. The double-stranded RNA molecule targeting the promoter region of the LHPP gene comprises two nucleic acid strands of 16 to 35 nucleotides in length, wherein one of the nucleic acid strands has at least 75% homology or complementarity to a target selected from the promoter region of the LHPP gene. The present invention also relates to pharmaceutical compositions comprising the small activating nucleic acids and optional pharmaceutically acceptable carriers, and methods for upregulating the expression of the LHPP gene in a cell and methods for treating diseases or conditions related to insufficient or decreased expression of LHPP gene by using the small activating nucleic acid molecules or the pharmaceutical compositions. | 2022-03-31 |
20220096517 | MicroRNA Compounds and Methods for Modulating MIR-10B Activity - Described herein are compositions and methods for the inhibition of miR-10b activity. The compositions may be administered to subjects with cancer, such as glioma. | 2022-03-31 |
20220096518 | COMPOSITIONS AND METHODS FOR CANCER THERAPY - One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described. | 2022-03-31 |
20220096519 | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING SPRAY DRIED VITAMIN B12 - The present invention relates to a solid pharmaceutical dosage form comprising at least one spray dried formulation of vitamin B12 and at least one further active pharmaceutical ingredient. Said at least one further active pharmaceutical ingredient is preferably metformin or a pharmaceutical acceptable salt thereof. When manufacturing the dosage form of the invention, uniformity of content is excellent. | 2022-03-31 |
20220096520 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT - The present disclosure provides a modified human protein having improved in vivo stability. The modified human protein has been altered from a wild-type human protein at either at least one ubiquitination site, at the signal peptide portion, or both. The protein of the disclosure can be produced from a codon optimized mRNA suitable for administration to a patient suffering from deficiency of the wild-type protein, wherein upon administration of the mRNA to the patient, the modified protein of the disclosure is expressed in the patient in therapeutically effective amounts. | 2022-03-31 |
20220096521 | HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF - The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof. | 2022-03-31 |
20220096522 | HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF - The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by inproved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof. | 2022-03-31 |
20220096523 | COMPOSITIONS FOR THE TREATMENT OF DRY EYE - The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals. | 2022-03-31 |
20220096524 | METHODS OF PROMOTING HEALTHY CATCH-UP GROWTH - A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch. | 2022-03-31 |
20220096525 | NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERS - Provided herein, are compositions based on retroviruses (e.g., lentiviruses) comprising one or more nucleic acid molecules encoding retroviral Pol polyprotein components and a nucleic acid molecule comprising one or more transgene sequences flanked by long terminal repeat sequences, for delivery of the one or more transgenes to a target cell ex vivo or in vivo. The compositions are useful for delivering to a target cell (e.g., hematopoietic stem cells (HSCs), liver cells, ocular cells, muscle cells, epithelial cells, T cells, etc.) and/or stably expressing any transgene (e.g., beta-globin, Factor VIII, RP GTPase regulator (RPGR), dystrophin, cystic fibrosis transmembrane conductance regulator (CFTR), a chimeric antigen receptor, etc.) with a biological effect to treat and/or ameliorate the symptoms associated with any disorder related to gene expression (e.g., sickle cell disease, beta-thalassemia, haemophilia B, retinitis pigmentosa, Duchenne muscular dystrophy, cystic fibrosis, cancer, etc.). | 2022-03-31 |